July 23, 2014 5:18 PM ET


Company Overview of Asuragen, Inc.

Company Overview

Asuragen, Inc., a RNA-based therapeutic and diagnostics company, provides molecular biology services. The company focuses on molecular oncology and genetic diseases, with emphasis on microRNA (miRNA). It offers diagnostic products, such as Signature genetic testing and oncology testing products, as well as controls and standards. The company also offers nucleic acid-based services, including analyte isolation/preparation, genomic profiling, miRNA/mRNA expression profiling, biomarker discovery, assay design and validation, CLIA-based clinical testing, bioinformatics, and regulatory and project management. In addition, it offers gene expression profiling, genotyping, miRNA expression profiling...

2150 Woodward Street

Suite 100

Austin, TX 78744

United States

Founded in 2005





Key Executives for Asuragen, Inc.

Chief Executive Officer and President
Chief Financial Officer
Age: 54
Senior Vice President and General Counsel
Senior Director of Clinical Affairs
Compensation as of Fiscal Year 2014.

Asuragen, Inc. Key Developments

Asuragen Receives New York State License for Molecular Genetic and Oncology Clinical Laboratory Testing

Asuragen, Inc. announced that it had received a clinical laboratory permit from the state of New York to offer Xpansion Interpreter, its reflex test for fragile X carriers and miRInform Thyroid for use in the management of patients with thyroid nodules. With this approval, Asuragen can now offer its CAP-certified CLIA laboratory Xpansion Interpreter and miRInform Thyroid Tests in all 50 states. Fragile X syndrome is the most common inherited cause of intellectual disability and autism. The likelihood of having a child with fragile X syndrome is linked to the number of CGG repeats and the number of AGG interruptions in the Fragile X Mental Retardation (FMR1) gene. Xpansion Interpreter is the first clinically available laboratory-developed FMR1 test that determines the total number of CGG repeats and number of AGG interruptions. Xpansion Interpreter can aid in personalizing the risk for at-risk patients of having a child with fragile X syndrome. Features of fragile X syndrome vary widely but can include mild to severe cognitive delays, seizures, behavioral differences such as perseverative speech and hand flapping, and characteristic facial features such as large ears and a long face. About 1 in 4,000 males and 1 in 8,000 females has fragile X syndrome. The molecular basis for fragile X syndrome is an increased number of trinucleotide CGG repeats in the 5' promoter region of the FMR1 gene. FMR1 alleles can be further categorized based on the number of CGG repeats, and premutation alleles may expand from parent to child to a full mutation that can cause features of fragile X syndrome. In addition, people with premutations may develop fragile X-associated Tremor/Ataxia Syndrome and women may develop fragile X-associated Primary Ovarian Insufficiency.

Asuragen Receives Notice of Patent Allowance for Broad Diagnostic Application of miR-21 in Cancer

Asuragen, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/890,398 with claims covering the detection of miR-21 across all cancers and for all sample types. miR-21 is over-expressed in almost all solid tumors including breast, colon, esophageal, head and neck, lung, pancreas, prostate, and stomach cancers. It is the only miRNA that is up regulated in nearly all classes of human cancers derived from connective tissues and epithelial, hematopoietic, germ or nervous cells. Further supporting the ubiquitous oncogenic role of miR-21, multiple scientific publications have shown that miR-21 plays an important role in virtually every cellular process involved in tumor development such as proliferation, angiogenesis, replicative immortalization, invasion and metastasis, genome instability and mutation, tumor-promoting inflammation, deregulation of cellular metabolism, evading growth suppressors, immune destruction and cell death.

Asuragen, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 03:00 PM

Asuragen, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 03:00 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Similar Private Companies By Industry

Company Name Region
AntiCancer, Inc. United States
nanoRETE, Inc. United States
Cardiac Support Systems, Inc. United States
Synthrx, Inc. United States
Ablitech, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Asuragen, Inc., please visit www.asuragen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.